Daily pill cuts breast cancer recurrence by 30%

A new pill could give some people with early-stage breast cancer another option for keeping the disease from coming back. The experimental drug, giredestrant, cut the risk of invasive breast cancer recurrence or death by 30% compared with standard hormone therapy in a large Phase 3 trial. That is the headline result from Roche's lidERA trial, which followed about 4,100 people with early-stage, oestrogen receptor-positive (ER-positive), HER2-negative breast cancer.

The drug improved invasive disease-free survival, but researchers don't yet have enough data to say it helps people live longer.

A pill designed to attack the cancer's hormone signal

Giredestrant is a once-daily pill designed to block and degrade oestrogen receptors. Because ER-positive breast cancers rely on oestrogen signaling to grow, disrupting that pathway is a cornerstone of treatment.

In the lidERA trial, 92.4% of people taking giredestrant were alive without invasive disease three years after treatment, compared with 89.6% of those receiving standard endocrine therapy. That may look like a modest difference at first glance, but the relative reduction in the risk of recurrence or death was 30%, enough for the trial to meet its primary goal.

The side-effect situation looks encouraging too

The drug did not just perform better on the main trial measure. It was also generally well tolerated. About 5.3% of people taking giredestrant stopped treatment because of adverse events, compared with 8.2% among those receiving standard endocrine therapy.

Roche is also presenting patient-reported outcomes at the 2026 ESMO Annual Meeting in Madrid, with the company saying the recurrence reduction did not come at the expense of quality of life or tolerability.

There is another promising result but it’s a different cancer setting

Giredestrant is also being studied in people with advanced ER-positive, HER2-negative breast cancer, but that's a separate use from the early-stage treatment tested in the lidERA trial. In the Phase 3 evERA trial, giredestrant combined with everolimus reduced the risk of disease progression or death by 44% compared with standard endocrine therapy plus everolimus.

Among people whose tumors carried an ESR1 mutation, the combination showed a 62% reduction in that risk.

Those results are promising, but they shouldn't be mixed together with the early-stage findings. One trial is looking at preventing invasive disease from returning after earlier treatment, while the other is dealing with advanced breast cancer.

Now the FDA gets to decide

The big next step is regulatory approval. The FDA accepted Roche's application for giredestrant as an adjuvant treatment for adults with stage I to III ER-positive, HER2-negative breast cancer under Priority Review. The agency is expected to make its decision by November 30, 2026.

If approved, the drug wouldn't automatically become the right treatment for everyone with breast cancer. Its use would depend on the final label, clinical guidance and an individual's circumstances.

For now, the interesting part is the major trial hurdle giredestrant has cleared. The longer-term question of whether that translates into people actually living longer still needs more time and data.

Source: Healthandme